Cell and gene therapy has evolved into one of the biopharma industry’s hottest markets, with a major splash of investment and a run of approvals anticipated in the coming years. To meet what’s likely to be massive demand for manufacturing capacity, industry experts are calling for “forward-looking” investments—but as one pointed out, those checks aren’t easy to write.
Image: As many as 10 to 20 new cell and gene therapies could be approved each year through 2025. (Gilead)
{iframe}https://www.fiercepharma.com/manufacturing/cell-and-gene-therapy-boom-coming-experts-at-novartis-kite-trumpet-need-for-capacity{/iframe}